Valeant auctions off Dendreon, skincare assets; Bayer to collaborate with the University of Pittsburgh
• A troubled Valeant has struck a deal to sell Dendreon and its prostate cancer vaccine Provenge to China’s Sanpower Group for $820 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
